AU5496500A - Retro-inverso peptides derived from interleukin-3 - Google Patents

Retro-inverso peptides derived from interleukin-3

Info

Publication number
AU5496500A
AU5496500A AU54965/00A AU5496500A AU5496500A AU 5496500 A AU5496500 A AU 5496500A AU 54965/00 A AU54965/00 A AU 54965/00A AU 5496500 A AU5496500 A AU 5496500A AU 5496500 A AU5496500 A AU 5496500A
Authority
AU
Australia
Prior art keywords
retro
interleukin
peptides derived
inverso peptides
inverso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU54965/00A
Other languages
English (en)
Inventor
D. Elliot Parks
David E. Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myelos Corp
Original Assignee
Myelos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myelos Corp filed Critical Myelos Corp
Publication of AU5496500A publication Critical patent/AU5496500A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU54965/00A 1999-06-16 2000-06-16 Retro-inverso peptides derived from interleukin-3 Abandoned AU5496500A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13968899P 1999-06-16 1999-06-16
US60139688 1999-06-16
PCT/US2000/016759 WO2000077028A1 (en) 1999-06-16 2000-06-16 Retro-inverso peptides derived from interleukin-3

Publications (1)

Publication Number Publication Date
AU5496500A true AU5496500A (en) 2001-01-02

Family

ID=22487853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54965/00A Abandoned AU5496500A (en) 1999-06-16 2000-06-16 Retro-inverso peptides derived from interleukin-3

Country Status (6)

Country Link
EP (1) EP1185552A1 (ja)
JP (2) JP2003502340A (ja)
AU (1) AU5496500A (ja)
CA (1) CA2376394A1 (ja)
IL (2) IL147093A0 (ja)
WO (1) WO2000077028A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
AU2003250697B2 (en) * 2002-07-30 2008-05-01 Stem Cell Therapeutics Inc. Oligodendrocyte production from multipotent neural stem cells
WO2004035086A2 (en) * 2002-10-16 2004-04-29 Hunter Samuel F Method for treatment of demyelinating central nervous system disease using gm-csf
US7695723B2 (en) * 2002-12-31 2010-04-13 Sygnis Bioscience Gmbh & Co. Kg Methods of treating neurological conditions with hematopoietic growth factors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700909A (en) * 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
US6271196B1 (en) * 1996-03-05 2001-08-07 Regents Of The University Of Ca Methods of alleviating neuropathic pain using prosaposin-derived peptides
EP0979238A4 (en) * 1997-03-05 2000-08-23 Univ California METHOD FOR HEALING NEUROPATHIC PAIN
US6458357B1 (en) * 1997-09-09 2002-10-01 Myelos Corporation Retro-inverso neurotrophic and analgesic peptides

Also Published As

Publication number Publication date
IL147093A (en) 2011-04-28
IL147093A0 (en) 2002-08-14
JP2011137019A (ja) 2011-07-14
CA2376394A1 (en) 2000-12-21
WO2000077028A1 (en) 2000-12-21
JP2003502340A (ja) 2003-01-21
EP1185552A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
AU7358700A (en) Dolastatin peptides
AU1951201A (en) Peptide antigens
GB0128994D0 (en) Peptides
AU4281999A (en) Peptide
AU2196101A (en) Complementary peptide ligands generated from the human genome
AU2002252801A1 (en) Peptides derived from colostrinin
HK1042307A1 (zh) 具有刺激胰島素分泌功能的肽
AU2973100A (en) Novel agouti and agouti-related peptide analogs
AU1574401A (en) Granulocyte peptide homolog zgpa1
AU5496500A (en) Retro-inverso peptides derived from interleukin-3
EP1159288A4 (en) ALPHA-CONOTOXIN PEPTIDES
AU5622700A (en) Retro-inverso peptides derived from leukemia inhibitory factor
AU2691500A (en) Novel polypeptide
AU4778600A (en) Novel polypeptide
AU1552800A (en) Coupled peptides
IL144376A0 (en) Peptides
AU3506800A (en) Leukocyte- and blood-associated proteins
AU6540500A (en) Retro-inverso peptides derived from interleukin-6
AUPQ386899A0 (en) Peptide compounds
AU2001278975A1 (en) Alpha-conotoxin peptides
AU2109200A (en) Polypeptide
EP1151100A4 (en) PEPTIDES DESIGNED TAU-CONOTOXINS
AU6637700A (en) Tryptase-like polypeptide ztryp1
AUPQ305799A0 (en) Peptides
AUPQ387399A0 (en) Peptides

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase